CRIDANIMOD

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H11NO3
Molecular Weight	253.2527
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CN1C2=C(C=CC=C2)C(=O)C3=C1C=CC=C3

InChI

InChIKey=UOMKBIIXHQIERR-UHFFFAOYSA-N

InChI=1S/C15H11NO3/c17-14(18)9-16-12-7-3-1-5-10(12)15(19)11-6-2-4-8-13(11)16/h1-8H,9H2,(H,17,18)

HIDE SMILES / InChI

Description
Sources: https://www.xeneticbio.com/news-media/press-releases/detail/38/xenetic-biosciences-announces-fda-acceptance-of
Curator's Comment: The description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT02064725 | https://clinicaltrials.gov/ct2/show/NCT03077698

Cridanimod (Virexxa) is a small-molecule immunomodulator and interferon inducer, which, in preliminary studies, has been shown to increase progesterone receptor expression in endometrial tissue. Restoration of progesterone receptor expression may re-sensitize endometrial tumor tissue to progestin therapy in previously unresponsive tumors. Cridanimod was originally developed by Polysan and Pharmsynthez and licensed to Xenetic Biosciences. Virexxa is currently being studied in an ongoing Phase 2 multi-national study in conjunction with progestin therapy for the treatment of endometrial cancer in women with the recurrent or persistent disease who have failed progestin monotherapy.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
progesterone receptor signaling pathway 2 Target ID: GO:0050847 Sources: https://www.xeneticbio.com/news-media/press-releases/detail/38/xenetic-biosciences-announces-fda-acceptance-of	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Recurrent or persistent endometrial carcinoma 2 Sources: https://clinicaltrials.gov/ct2/show/NCT02064725	Primary		Phase II 1132	Unknown Approved Use Unknown
Endometrial cancer 43 Sources: https://clinicaltrials.gov/ct2/show/NCT03077698	Primary		Phase II 1132	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
HIV-1 neutralization and tumor cell proliferation inhibition in vitro by simplified analogues of pyrido[4,3,2-mn]thiazolo[5,4-b]acridine marine alkaloids.	1992 Jul 24	1495008
Correlations between in vitro effects of preparations of interferon and its inducers on blood cells in patients with multiple sclerosis.	2001 Apr	11550032
Regulation of cytokine mRNAs by interferon and interferon inducers.	2002 Jul	12687259
[Neuroimmunopathological mechanisms of preclinical epileptogenesis and their correction by cycloferon].	2003	14763254
[Cytokinin inducing and antiviral activity of cycloferon on experimental herpetic infection].	2003 Jul-Aug	12966893
[Neuroimmunopathologic aspects of epilepsy].	2004	15455693
[The preclinical diagnosis, prevention and treatment of postoperative iridocyclitis in patients after intraocular aphakia correction].	2004 Jul-Aug	15384841
[Cycloferon--a new domestic preparation for the prophylaxis of influenza and other acute respiratory viral infections].	2004 Nov-Dec	15636140
[Cyclopheron pretreatment in opisthorchiasis management in patients with viral hepatitis C].	2005	16404860
[Individual changes of gene expression in the interferon system in human blood cells due to amixin and cycloferon].	2005 Mar-Apr	15881395
[Influence of cycloferon on the biological properties of bacterial intracellular pathogens].	2005 May-Jun	16028504
[Effect of aerosol therapy with cyclopheron in patients with chronic rhinitis].	2006 Jun	16905806
[Some pathogenic mechanisms of aerozol-therapy including cyclopheron treatment in patients with chronic rhinitis].	2006 May	16783061
[Cycloferon in the treatment of infectious diseases].	2008	18942425
[Type 1 and type 2 interferon inductor (cycloferon) in therapy of children with pyelonephritis associated with herpes viruses].	2009	20052918
[Pathogenetic therapy of tuberculosis of respiratory organs during sanatorium-and-spa treatment].	2009 Nov-Dec	20017380
[Cycloferon efficacy in viral and bacterial diseases of children (clinical review)].	2010	21574424
[Optimization of prophylaxis of relapses of primary erysipelas with the use of cyclopheron].	2010	21395032
[Use of cycloferon in the treatment of patients with pulmonary tuberculosis with mild clinical manifestations].	2010	21381350
[Clinical laboratory approaches to parodontitis treatment optimization].	2010	21311440
[Effectiveness of cycloferon liniment in a complex treatment, and monitoring of cytokine profile of gingival fluid of patients with paradontitis].	2010	21207889
[Optimization of parodontitis treatment of patients with tuberculosis].	2010	21186645
[Efficacy of cycloferon in the treatment of brucellosis].	2010	20608067
[Combined cycloferon treatment of tuberculosis in patients infected with HIV].	2010 Jul	20821978
[Focal immunophysiotherapy in combined treatment of men with manifestations of papilloma virus infection].	2010 Nov-Dec	21427998

Patents

Sample Use Guides

In Vivo Use Guide

Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or medroxyprogesterone acetate (200 mg p.o./ day).

Route of Administration: Intramuscular

In Vitro Use Guide

Unknown

Name

Type

Language

CRIDANIMOD

Official Name

English

Cridanimod [WHO-DD]

Common Name

English

cridanimod [INN]

Common Name

English

9-OXO-10-ACRIDANACETIC ACID

Systematic Name

English

10-(CARBOXYMETHYL)-9-ACRIDINONE

Systematic Name

English

10(9H)-ACRIDINEACETIC ACID, 9-OXO-

Systematic Name

English

Classification Tree Code System Code

WHO-ATC

L03AX18